Psoriatic Arthritis
News
Rapid shift to adalimumab biosimilars in Denmark contrasts with U.S. experience
The Danish health care system’s shift to adalimumab biosimilars led to substantial decreases in cost.
Multimedia
Psoriasis Therapy During the COVID-19 Pandemic: Should Patients Continue Biologics?
Latest News
AAD-NPF releases first guidelines for nonbiologic treatments of psoriasis
Guidelines for nonbiologic systemic agents for psoriasis provide strong evidence for use of apremilast and guidance for off-label drugs.
Conference Coverage
Secukinumab outperforms adalimumab overall for PsA
MAUI, HAWAII – Results of the 52-week, head-to-head EXCEED study.
News
Specific markers detect psoriatic disease inflammation without elevated CRP
Clinical subsets of psoriatic disease based on organ involvement are characterized by specific inflammation marker profiles in the absence of...
News
Psoriasis elevates cancer risk
No increased cancer risk occurred in psoriasis patients treated with biologics or in patients with psoriatic arthritis.
News
Tildrakizumab signals safe for pregnant psoriasis patients
Post hoc analysis of pregnancy outcomes yielded no new concerns for spontaneous abortions or congenital anomalies in women of childbearing age...
Conference Coverage
Registry data reveal temporal relationship between psoriasis symptoms and PsA onset
ATLANTA – Age at the onset of psoriasis was the main factor that determined PsA symptom synchronicity, according a study of data from the PsART...
News
Apremilast more likely to succeed with moderate psoriatic arthritis activity
The results of a pooled analysis of the PALACE 1-3 trials “provide a framework of reference for the selection and monitoring of patients with the...
Conference Coverage
Bimekizumab elevates psoriasis therapy
MADRID –